-+ 0.00%
-+ 0.00%
-+ 0.00%

*Neurocrine: INGREZZA Full Yr 2026 Guidance Increased From Range of $2.7B to $2.8B Up to $2.825B to $2.875B >NBIX

Dow Jones·07/30/2026 20:04:00

Please log in to view news